VisionGate Claims Advance

Phoenix-based VisionGate, which is developing non-invasive tests for the early detection of lung cancer, claimed a "major advance" in its efforts this morning. The firm said it has fully automated its Cell-CT 3D imaging system, which it says is a major milestone for the company. The firm said the milestone "sets the stage" for submission of its first application to the Food and Drug Administration (FDA). VisionGate said the milestone came as a result of a $2.6M, NIH grant from the BRDG-SPAN program (Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies). VisionGate raised $2M in a funding round in October for its efforts, from un-named investors.